Study of Pyrotinib in Patients With Human Epidermalgrowth Factor Receptor 2 (HER2) Positive Advanced Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Pyrotinib
Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Collaborators: Chinese Academy of Medical Sciences